Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0BZ7W
|
||||
| Former ID |
DAP000376
|
||||
| Drug Name |
Tolterodine
|
||||
| Synonyms |
Tolterodina; Tolterodinum; Detrol (TN); Detrusitol (TN); Kabi-2234; 2-[(1R)-3-(diisopropylamino)-1-phenylpropyl]-4-methylphenol; 2-[(1R)-3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-methylphenol; 2-[3-[Bis(1-methylethyl)amino]-1-phenylpropyl]-4-methylphenol; 2-{(1R)-3-[bis(1-methylethyl)amino]-1-phenylpropyl}-4-methylphenol
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Overactive bladder [ICD9: 596.51; ICD10:N32.81] | Approved | [1] | ||
| Therapeutic Class |
Antispasmodics
|
||||
| Company |
Pfizer Pharmaceuticals
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C22H31NO
|
||||
| InChI |
InChI=1S/C22H31NO/c1-16(2)23(17(3)4)14-13-20(19-9-7-6-8-10-19)21-15-18(5)11-12-22(21)24/h6-12,15-17,20,24H,13-14H2,1-5H3/t20-/m1/s1
|
||||
| InChIKey |
OOGJQPCLVADCPB-HXUWFJFHSA-N
|
||||
| CAS Number |
CAS 124937-51-5
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
9952, 7847712, 14777260, 14801661, 23936567, 29215497, 36887062, 46508059, 48416646, 49666284, 50070814, 56322577, 56464111, 57404545, 75101389, 85083128, 89736135, 92712344, 93166476, 93618065, 103463555, 104050603, 104179074, 104630915, 118048147, 118048994, 124799394, 126625639, 126656774, 126668318, 127315558, 127315559, 127315560, 128837711, 135651269, 137028044, 140085486, 143493272, 144205290, 151981130, 152034997, 152236221, 164234496, 164765641, 164787750, 170465337, 172440007, 175265551, 176485082, 179116925
|
||||
| ChEBI ID |
ChEBI:9622
|
||||
| SuperDrug ATC ID |
G04BD07
|
||||
| SuperDrug CAS ID |
cas=124937515
|
||||
| Target and Pathway | |||||
| Target(s) | Muscarinic acetylcholine receptor M3 | Target Info | Antagonist | [2], [3] | |
| KEGG Pathway | Calcium signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Cholinergic synapse | |||||
| Regulation of actin cytoskeleton | |||||
| Insulin secretion | |||||
| Salivary secretion | |||||
| Gastric acid secretion | |||||
| Pancreatic secretion | |||||
| PANTHER Pathway | Alzheimer disease-amyloid secretase pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Muscarinic acetylcholine receptor 1 and 3 signaling pathway | |||||
| PathWhiz Pathway | Gastric Acid Production | ||||
| Reactome | Muscarinic acetylcholine receptors | ||||
| Acetylcholine regulates insulin secretion | |||||
| G alpha (q) signalling events | |||||
| WikiPathways | Monoamine GPCRs | ||||
| Calcium Regulation in the Cardiac Cell | |||||
| Regulation of Actin Cytoskeleton | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| Integration of energy metabolism | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| GPCRs, Other | |||||
| References | |||||
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | ||||
| REF 2 | Knockouts model the 100 best-selling drugs--will they model the next 100? Nat Rev Drug Discov. 2003 Jan;2(1):38-51. | ||||
| REF 3 | Signal transduction underlying carbachol-induced contraction of human urinary bladder. J Pharmacol Exp Ther. 2004 Jun;309(3):1148-53. Epub 2004 Feb 9. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.